{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"59.4","value":"49.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Cmin was defined as the minimum observed plasma concentration of retifanlimab.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received retifanlimab 500 milligrams (mg) every 4 weeks (Q4W) for up to thirteen 28-day cycles (1 year) in the absence of disease progression, intolerable toxicity, death, withdrawal of consent, being lost to follow-up, or premature discontinuation of all assigned study drug administration or for any other reason. Participants also received the standard-of-care chemotherapy regimen of up to 6 induction cycles (24 weeks) of carboplatin (AUC5 on Day 1) and paclitaxel (80 mg per meters squared \\[mg/m\\^2\\] on Days 1, 8, and 15).","id":"OG000","title":"Retifanlimab 500 mg Q4W + Chemotherapy"},{"description":"Participants received matching placebo Q4W for up to thirteen 28-day cycles (1 year) in the absence of disease progression, intolerable toxicity, death, withdrawal of consent, being lost to follow-up, or premature discontinuation of all assigned study drug administration or for any other reason.","id":"OG001","title":"Placebo + Chemotherapy"},{"description":"In the optional monotherapy treatment period, participants randomized to placebo + chemotherapy who experienced documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) verified by the blinded independent review committee (BICR) had the opportunity to receive open-label retifanlimab monotherapy for up to thirteen 28-day cycles (1 year).","id":"OG002","title":"Retifanlimab 500 mg Q4W"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Evaluable Population","reportingStatus":"POSTED","timeFrame":"preinfusion on Day 1 of Cycles 1, 2, 4, 6, 8, and 12; immediately after infusion on Day 1 of Cycles 1 and 4","title":"Cmin of Retifanlimab at Steady State When Administered With Carboplatin-paclitaxel","type":"SECONDARY","unitOfMeasure":"mg/L"}